1. Nasonov, E.V., Mazurov, V.I., Usacheva, Y.V., Chernyaeva, E.V., Ustyugov, Y.Y., et al., Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases, Nauchno-Prakt.
Revmatol., 2017, vol. 55, no. 2, pp. 201–210.
2. Nasonov, E.L., Beketova, T.V., Ananyeva, L.P., Vasilyev, V.I., Solovyev, S.K., and Avdeeva, A.S., Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases, Nauchno-Prakt.
Revmatol., 2019, vol. 57, pp. 1–40.
3. Barnas, J., Looney, R., and Anolik, J., B cell targeted therapies in autoimmune disease, Curr. Opin. Immunol., 2019, vol. 61, pp. 92–99.
4. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab (Anti-B-Cell Therapy in Rheumatology: Focus on Rituximab), Nasonov, E.L., Ed., Moscow: IMA-PRESS, 2012.
5. Denton, C.P. and Khanna, D., Systemic sclerosis, Lancet, 2017, vol. 390, no. 10103, pp. 1685–1699.